NIH Highlighted Topic: Advancing Toward a Cure for Acquired Neuropathy
Below is a brief summary. Please check the full solicitation before applying (link in resources section).
Executive Summary:
The National Institutes of Health (NIH) is encouraging innovative research proposals focused on advancing disease-modifying therapies, biomarkers, diagnostics, and clinical outcome measures for acquired neuropathy (AN). This highlighted topic supports multidisciplinary research aimed at improving understanding of neuropathy pathophysiology and accelerating the development of interventions capable of preventing, slowing, or reversing nerve damage associated with inflammatory, autoimmune, diabetic, and cancer-related neuropathies.
NIH is particularly interested in projects targeting major unmet needs in acquired neuropathy research, including biomarker discovery, improved clinical assessment tools, and regenerative or neuroprotective therapeutics. Companies developing neuromodulation technologies, AI-enabled diagnostics, biomarker analytics platforms, regenerative medicine solutions, digital health tools, peripheral nerve therapies, or advanced neurodiagnostic systems may be strong candidates for funding.
Areas of interest include diabetic neuropathy, chemotherapy-induced peripheral neuropathy (CIPN), autoimmune neuropathies, autonomic dysfunction, regenerative medicine, translational disease models, predictive analytics, wearable diagnostics, clinical monitoring systems, and novel therapeutic screening platforms. NIH is also encouraging projects that address disease heterogeneity, sex differences, socioeconomic influences, and personalized approaches to neuropathy treatment and monitoring.
Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for additional commercialization and follow-on funding depending on project scope and translational impact.
This highlighted topic is supported primarily by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Cancer Institute (NCI), and the Office of Research on Women’s Health (ORWH), all of which are seeking transformative innovations that improve acquired neuropathy diagnosis, monitoring, treatment, and patient outcomes.
How much funding would I receive?
Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.
What could I use the funding for?
Funding may support the research, development, validation, and commercialization of diagnostics, biomarkers, therapeutics, neuromodulation systems, regenerative medicine technologies, and clinical monitoring tools related to acquired neuropathy.
Eligible activities may include:
Biomarker discovery and predictive analytics platforms for neuropathy detection
AI and machine learning tools for neuropathy diagnosis and progression monitoring
Regenerative medicine and neuroprotective therapeutic development
Neuromodulation and peripheral nerve stimulation technologies
Clinical outcome measurement and digital assessment systems
Wearable devices and remote monitoring technologies for neuropathy patients
Translational animal models and organoid-based neuropathy research systems
Therapeutics for diabetic neuropathy and autonomic neuropathy
Chemotherapy-induced peripheral neuropathy (CIPN) prevention and treatment technologies
Autoimmune neuropathy therapeutic platforms
Computational biology and bioinformatics tools for neuropathy research
Personalized medicine approaches for neuropathy management
Imaging and diagnostic systems for peripheral nerve function assessment
Drug screening and therapeutic validation platforms
Pain management and sensory function monitoring technologies
Prototype development, translational studies, and clinical validation research
Commercialization planning, regulatory preparation, and manufacturing scale-up activities
Funding may also support personnel, laboratory testing, software engineering, AI model development, cloud infrastructure, biomarker analysis, preclinical studies, wearable integration, bioinformatics pipelines, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable neurology or biotechnology solution aligned with NIH priorities.
Are there any additional benefits I would receive?
Beyond the formal funding award, awardees gain several strategic advantages:
Government Validation and Credibility:
Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.Enhanced Visibility and Market Recognition:
Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.Access to the Federal Innovation Ecosystem:
Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.Stronger Commercial and Exit Potential:
By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.
What is the timeline to apply and when would I receive funding?
Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.
Where does this funding come from?
Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.
Who is eligible to apply?
Applicants must be U.S. small business concerns (SBCs) that:
Are organized for profit with a U.S. place of business.
Have ≤ 500 employees including affiliates.
Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.
What companies and projects are likely to win?
Projects that demonstrate:
A clear unmet medical or public-health need,
Strong scientific rationale and feasibility,
High commercialization potential, supported by a realistic market and regulatory strategy, and
Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).
Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.
Are there any restrictions I should know about?
Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.
Foreign entities are not eligible.
Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.
How long will it take me to prepare an application?
For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.
How can BW&CO help?
Our team specializes in complex federal R&D proposals and can:
Triple your likelihood of success through proven strategy and insider-aligned proposal development
Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations
Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.
